Latest news:
Seattle Genetics Inc. (NASDAQ:SGEN) and Millennium Pharmaceuticals Inc. partnered with Ventana Medical Systems Inc. to develop and commercialize a companion diagnostic for cancer drug Adcetris brentuximab vedotin. The partners said the molecular diagnostic will identify patients who might respond to treatment with Adcetris based on CD30 expression levels in tissue specimens. Adcetris is an antibody-drug conjugate (ADC) composed of an anti-CD30 mAb and monomethyl auristatin E (MMAE). Seattle Genetics and Millennium will use the diagnostic in two planned Phase III trials of Adcetris to treat CD30-positive cutaneous T cell lymphoma and CD30-positive mature T cell lymphomas.
What is interesting here is that there is hope that “the molecular diagnostic will identify patients who might respond to treatment with Adcetris”. Basically, why not? Well, I have already written about such possibilities but in application to another type of oncological disease.
From here: “Intratumor heterogeneity can lead to underestimation of the tumor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges to personalized-medicine and biomarker development. Intratumor heterogeneity, associated with heterogeneous protein function, may foster tumor adaptation and therapeutic failure through Darwinian selection”.
Probably this time this approach will work for lymphoma – who knows? Let them try.
No comments:
Post a Comment